GILD - Gilead Sciences in charts: Revenue from oncology rises most among products; Veklury dips in Q1
2024-04-25 16:19:35 ET
More on Gilead Sciences
- Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?
- Gilead Sciences: Some Signs Of An Impending Bottom
- Gilead Sciences Finally Starts Succeeding
- Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus
- FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk